Fleury stock
Price history
+41.23% over the period1 year: from R$15.23 (November 24, 2025) to R$21.51 (November 22, 2026), +41.23%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 22, 2026 | R$21.51 |
| October 30, 2026 | R$20.47 |
| September 30, 2026 | R$22.79 |
| August 31, 2026 | R$19.68 |
| July 31, 2026 | R$17.14 |
| June 30, 2026 | R$15.40 |
| May 29, 2026 | R$15.39 |
| April 30, 2026 | R$16.08 |
| March 31, 2026 | R$15.93 |
| February 27, 2026 | R$16.82 |
| January 30, 2026 | R$16.62 |
| December 30, 2025 | R$15.00 |
| November 28, 2025 | R$16.05 |
| November 24, 2025 | R$15.23 |
At a glance
The company
Provide diagnostic imaging, clinical analysis, fertility and infusion services in Brazil through two operating segments
Latest results
Quarter to September 30, 2026 · EPS R$0.49 (estimate R$0.43)
TickerLandia's take on Fleury
- Priced as usual relative to earnings: P/E on the latest fiscal year 19 vs a median of 20 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 15 vs 29 (−47%) in a group of 10.
- Strong point: Market momentum (93/100 in its group). Weak point: Financial strength (29/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−24.92% from the 52-week high
Analysts · 12 analysts
Average targetR$21.99+2.24% vs. price
Buy 3 · Hold 7 · Sell 2 · Hold
TickerLandia Fingerprint: Fleury
Compared with similar companies: very low price, very strong momentum, and very high growth.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 317 Latin American stocks.
Pricevery low6
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 15.0 2 Forward P/E 12.8 2 EV/EBITDA 7.53 2 Price/book 2.14 13 Price/sales 1.29 9 Profitabilityaverage43
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 27.3% 9 Operating margin 16.0% 43 Net margin 8.6% 46 ROE 14.0% 60 ROA 6.4% 57 Earnings stabilityhigh78
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.0% 94 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 61 Growthvery high82
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +13.40% 76 Earnings growth (year over year) +43.20% 82 Average revenue growth (3 years) +22.93% 87 Financial strengthlow29
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 2.12 69 Net debt/EBITDAcounts in reverse: lower means more financial strength 2.86 22 Interest coverage 1.64 13 Debt/equitycounts in reverse: lower means more financial strength 1.15 13 Dividendhigh77
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 17 years 56 Dividend yield 6.0% 97 Payout ratio 86.0% 78 Market momentumvery strong93
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (6 months) +47.07% 99 Relative strength (3 months) +18.70% 89 Distance from 200-day average +18.05% 95 1-year return +37.62% 88 Riskhigh61
How much the price swings.
Metric Value Position in group Volatility (60 days) 59.7% 78 Beta (1 year) 1.16 54 Maximum drawdown (12 months) 28.9% 51
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Fleury is priced as in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Fleury's P/E today is 19.1, in line with the median of its last 10 fiscal years (19.8; between 10.7 and 33.3 from 2016 to 2025). Fleury's P/E (trailing 12 months): 15.0, −47% against the median of a group of 10 similar companies (28.6).
Compared with 10 similar companies
| Metric | Fleury | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 15.0 | Low | |
| Forward P/E | 12.8 | Low | |
| Operating margin | 16.0% | Middle | |
| ROE | 14.0% | High | |
| Debt/equity | 1.15 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Fleury. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
R$2.32B
Latest quarter · Q2 2026
Net income
R$221.85M
Latest quarter · Q2 2026
Quarterly net margin
9.6%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- R$11.69B
- P/E
- 15.0
- EPS
- R$1.43
- Volume
- 5.53M
- Daily trading
- €18.91M
- Dividend yield
- 1.54%
- Last ex-dividend on August 12, 2026
How Fleury is changing
All resultsRevenue grew 22.8% a year on average over the last 5 years
Operating margin fell from 16.6% to 15.1%
Shares outstanding up 62.3% in 5 years
Returns
Fleury returns with dividends
R$1,000 invested in Fleury 5 years ago, on November 22, 2021, would be worth R$1,617 today with dividends reinvested: +61.72% in total, +10.09% per year. On price alone it would be R$1,219 (+21.92%).
| Period | Fleury | Ibovespa | R$1,000 becomes |
|---|---|---|---|
| 1 month | −22.68% | −18.87% | R$773 |
| 6 months | +37.09% | −5.58% | R$1,371 |
| Year to date | +43.40% | +3.26% | R$1,434 |
| 1 year | +52.30% | +7.15% | R$1,523 |
| 3 years | +54.94% | +32.01% | R$1,549 |
| 5 years | +61.72% | +62.92% | R$1,617 |
| 10 years | +92.18% | +168.55% | R$1,922 |
Over the last 6 months it has done better than 84% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. Ibovespa: with dividends. Calculate your investment
The chart in detail
Fleury: technical analysis
Fleury shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 31.9% below its all-time closing high (R$31.59, February 5, 2020).
- Trend
- No clear trend
- RSI (14 sessions)
- 46
- Between 30 and 70
- vs 200-session average
- +17.90%
Support and resistance
Price areas where Fleury has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last priceR$21.51
- SupportR$21.36−0.70%2 touches, last on November 11, 2026
- SupportR$17.91−16.74%2 touches, last on April 14, 2026
- SupportR$16.89−21.48%2 touches, last on July 17, 2026
Volatility and risk
Over the last year it has moved roughly in line with the Ibovespa.
- Beta (1 year) vs Ibovespa
- 1.16
- Volatility (60 sessions, annualised)
- 59.7%
- Largest fall in the last year
- −28.87%
In session, November 22, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Fleury: seasonality
Average monthly price change over 17 years
Over the last 17 years, the strongest month for Fleury has been August: +3.15% on average, positive in 12 years out of 17. The weakest has been February: −1.05% on average, positive in 7 years out of 17. November, the current month, has been positive in 6 years out of 16 (+0.10% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.62% | +0.27% | 10 of 17 |
| February | −1.05% | −1.12% | 7 of 17 |
| March | −0.98% | −2.35% | 7 of 17 |
| April | +1.26% | +0.53% | 9 of 17 |
| May | +2.73% | +3.60% | 11 of 17 |
| June | +2.54% | +5.63% | 12 of 17 |
| July | +1.58% | +2.05% | 11 of 17 |
| August | +3.15% | +2.99% | 12 of 17 |
| September | +0.44% | −0.54% | 8 of 17 |
| October | −0.98% | −2.00% | 6 of 17 |
| November | +0.10% | −2.90% | 6 of 16 |
| December | +0.04% | +0.97% | 9 of 16 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Fleury and its competitors
Diagnostic Medicine, one of the two segments of Fleury S.A. and its subsidiaries, centers on diagnostic imaging and clinical analysis, alongside fertility services and infusions, all provided in Brazil. The second segment, Integrated Medicine, groups medical services that include laboratory support, health management, orthopedics, ophthalmology, toxicological tests and assistance medicine. The group also runs a health platform, an immunobiological drug infusion center and ophthalmology service centers.
- Headquarters
- São Paulo, Brazil
- Employees
- 32,000
- Founded
- 1926
- Chief executive
- Jeane Tsutsui
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| FleuryFLRY3 | $1.97B | 16.0% | 15.0 | +37.09% |
| Diagnosticos da AmericaDASA3 | $686.17M | 10.9% | — | +8.67% |
| DiagnostykaDIA | $1.27B | 14.9% | 20.2 | −6.62% |
| DiaSorinDIA | $4.21B | 22.3% | 28.6 | +14.88% |
| Sonic HealthcareSHL | $7.13B | 9.3% | 17.6 | +17.41% |
| WuXi XDC Cayman2268 | $9.64B | 28.1% | 46.6 | +3.47% |
Same industry or related industries, similar size. Compare Fleury with its competitors · Full profile
